NewsBenzingaMacroGenics、進行固形腫瘍患者を対象とした、非開示標的に向けた抗体薬物複合体MGC030の第1相試験で最初の患者への投与を開始 MacroGenics、進行固形腫瘍患者を対象とした、非開示標的に向けた抗体薬物複合体MGC030の第1相試験で最初の患者への投与を開始 Benzinga 2026.10.15 20:06 (GMT+0) Open on Benzinga Other news Freshworks Stock Has Strong Momentum at New 52-Week Highs, But There’s 1 Reason for Caution Why Is Snowflake Stock Surging Monday? 18 Globo Titles Heading To Netflix In Unprecedented Licensing Agreement ImmunityBio Study Shows Long-Term Success for Bladder Cancer Treatment RBC Capital Maintains Outperform on Regions Financial, Lowers Price Target to $32 Wells Fargo Maintains Equal-Weight on Greif, Lowers Price Target to $88
